Malignant lymphoma in which the majority of neoplastic cells within the follicles are large cleaved or noncleaved cells. The degree to which the follicular center cells retain their ability to form follicles varies with the state of B-cell transformation.
| Synonym |
|---|
| Follicular Mixed-Cell Lymphoma |
| Follicular Lymphoma, Grade 2 |
| Lymphoma, Lymphocytic, Nodular, Poorly-Differentiated |
| Lymphoma, Lymphocytic, Nodular, Poorly Differentiated |
| Follicular Lymphoma, Grade 1 |
| Follicular Lymphoma, Giant |
| Follicular Lymphoma |
| Follicular Large-Cell Lymphoma |
| Nodular Large Follicular Center-Cell Lymphoma |
| Lymphoma, Giant Follicular |
| Lymphoma, Large-Cell, Follicular |
| Brill-Symmers Disease |
| Lymphoma, Small Lymphoid, Follicular |
| Lymphoma, Follicular, Grade 3 |
| Lymphoma, Follicular Large-Cell |
| Lymphoma, Small Cleaved Cell, Follicular |
| Large Lymphoid Lymphoma, Nodular |
| Mixed-Cell Lymphoma, Follicular |
| Follicular Lymphoma, Grade 3 |
| Giant Follicular Lymphoma |
| Large-Cell Lymphoma, Follicular |
| Lymphoma, Large Cell, Follicular |
| Lymphoma, Nodular, Mixed Small and Large Cell |
| Lymphocytic Lymphoma, Nodular, Poorly-Differentiated |
| Lymphoma, Follicular, Mixed Cell |
| Lymphoma, Small Follicular Center-Cell |
| Lymphoma, Follicular, Mixed Lymphocytic-Histiocytic |
| Lymphoma, Follicular, Mixed Small and Large Lymphoid |
| Lymphoma, Small Cleaved-Cell, Follicular |
| Lymphoma, Mixed-Cell, Follicular |
| Lymphoma, Follicular, Small and Large Cleaved Cell |
| Lymphoma, Nodular |
| Lymphoma, Nodular, Mixed Lymphocytic-Histiocytic |
| Lymphoma, Nodular, Mixed Lymphocytic Histiocytic |
| Lymphocytic Lymphoma, Nodular, Poorly Differentiated |
| Lymphoma, Histiocytic, Nodular |
| Lymphoma, Follicular, Small and Large Cleaved-Cell |
| Lymphoma, Follicular, Grade 1 |
| Lymphoma, Nodular, Large Follicular Center-Cell |
| Lymphoma, Nodular, Large Follicular Center Cell |
| Small Follicular Center-Cell Lymphoma |
| Lymphoma, Follicular, Grade 2 |
| Small Cleaved-Cell Lymphoma, Follicular |
| Lymphoma, Large Lymphoid, Nodular |
| Histiocytic Lymphoma, Nodular |
| Excerpt | Reference |
|---|
| "The follicular lymphomas are the most common subtype of indolent non-Hodgkin's lymphoma in adults, with approximately 20,000 new cases annually in the United States, most of which are disseminated at diagnosis." | ( Peterson, BA, 1999) |
| "Follicular lymphomas are characterized by relatively long median survivals and a continuous pattern of relapse." | ( Horning, SJ, 2000) |
| "Advanced stages of follicular lymphoma are deemed incurable by conventional approaches." | ( Brezinschek, R; Höfler, G; Jäeger, G; Linkesch, W; Neumeister, P; Quehenberger, F; Sill, H, 2002) |
| "Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy." | ( Braziel, RM; Fisher, RI; Gaynor, ER; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Rivkin, SE; Unger, JM, 2003) |
| "Follicular lymphoma is characterized by the t(14;18)(q32;q21) translocation, which juxtaposes Ig heavy chain gene (IgH) sequences with the BclII gene." | ( Dessars, B; El Housni, H; Heimann, P; Swillens, S, 2006) |
| "Follicular lymphoma is the second most common lymphoma throughout the world." | ( Fernández Zubillaga, A; González-Barón, M; Moreno García, V; Redondo, A, 2008) |
| "Follicular lymphoma is the most common form of lymphoma in Europe and the USA." | ( Baccarani, M; Cabras, MG; De Luca, S; De Renzo, A; Derenzini, E; Fabbri, A; Fanti, S; Fattori, P; Fina, M; Gobbi, M; Guardigni, L; Marchi, E; Musuraca, G; Pellegrini, C; Perotti, A; Piccaluga, PP; Pileri, S; Pulsoni, A; Rigacci, L; Ronconi, S; Stefoni, V; Tani, M; Voso, MT; Zaccaria, A; Zinzani, PL, 2008) |
| "Follicular lymphoma is characterized by the t(14;18) translocation resulting in constitutive expression of BCL-2 protein; however approximately 10-15% of follicular lymphomas do not express BCL-2 protein, and a small fraction of these cases does not exhibit translocation of the BCL-2 gene either." | ( Balogh, Z; Bödör, C; Csernus, B; Csomor, J; Deák, L; Gagyi, E; Matolcsy, A; Reiniger, L; Szepesi, A; Timár, B, 2008) |
| "Follicular lymphoma is an indolent and usually incurable disease." | ( Ghielmini, M, 2010) |
| "The follicular lymphomas are indolent diseases that are highly responsive to various combinations of standard chemotherapy drugs." | ( Cheson, BD, 2011) |
| "Follicular lymphoma is a heterogeneous disease in which some patients present an indolent evolution for decades and others, a rather aggressive form of the disease requiring immediate therapy." | ( Salles, G; Sarkozy, C, 2013) |
| "Follicular lymphoma is a clinically and genetically heterogeneous disease, but the prognostic value of somatic mutations has not been systematically assessed." | ( Connors, JM; Dreyling, M; Ducar, M; Ennishi, D; Feller, AC; Gascoyne, RD; Hansmann, ML; Hiddemann, W; Horn, H; Hoster, E; Hother, C; Jurinovic, V; Klapper, W; Kopp, N; Kridel, R; Leich, E; Moccia, AA; Möller, P; Mottok, A; Murakami, M; Neuberg, D; Ott, G; Pastore, A; Pott, C; Rosenwald, A; Sehn, LH; Shulha, HP; Staiger, AM; Stein, H; Sunkavalli, A; Szczepanowski, M; Unterhalt, M; Van Hummelen, P; Weigert, O; Weinstock, DM, 2015) |
| "Follicular lymphoma is an indolent non-Hodgkin lymphoma that is most commonly diagnosed in elderly individuals." | ( Cordoba, R; Machan, S; Pérez-González, Y; Plaza, C; Requena, L; Rodriguez-Pinilla, M, 2020) |
| "Follicular lymphoma is a common indolent non-Hodgkin lymphoma with survival improving in the modern era." | ( Nastoupil, LJ, 2021) |
| "Follicular lymphoma is an indolent lymphoma which does not limit life expectancy in most patients; however, approximately 20% of patients will experience progression of disease within 24 months (POD24) of diagnosis and have inferior survival outcomes." | ( Casulo, C; Wallace, D, 2021) |
| "Follicular lymphoma is the second most common type of non-Hodgkin lymphoma, and the disease course is usually characterized by an indolent clinical course." | ( Miyazaki, K, 2022) |
| "Follicular lymphoma is an indolent lymphoma that remains incurable with standard approaches." | ( Ngu, H; Okosun, J; Phillips, T; Sehn, LH; Takiar, R, 2022) |
| Excerpt | Reference |
|---|
| "Ten patients with progressive follicular lymphomas (seven with follicular mixed lymphomas, three with follicular, small cleaved cell lymphomas) with clinical indications for systemic therapy received parenteral suramin." | ( Cooper, MR; Kohler, D; La Rocca, RV; Myers, CE; Stein, CA; Uhrich, M; Weinberger, E, 1992) |
| "Thirty-eight patients with follicular lymphoma (age range 29-61 years, median 43) have been treated to date." | ( Arnott, S; Clark, P; Cotter, F; Davis, CL; Dorey, E; Evans, ML; Norton, A; Price, CG; Rohatiner, AZ; Sterlini, J, 1991) |
| "Since June 1985, 121 patients with follicular lymphoma aged 24-61 years (median 43) have received myeloablative therapy (cyclophosphamide: 60 mg/kg x 2, + total body irradiation: 200 cGy x 6) with autologous bone marrow transplantation (CY+TBI+ABMT) as consolidation of 2nd or subsequent remission." | ( Freedman, A; Lim, J; Lister, TA; Nadler, L; Rohatiner, AZ, 1994) |
| "Newly diagnosed follicular lymphoma patients with a low tumor burden (n = 193) were randomly assigned to one of three arms: arm 1, no initial treatment (n = 66); arm 2, prednimustine 200 mg/m2/d for 5 days per month for 18 months (n = 64); or arm 3, interferon alfa 5 MU/d for 3 months then 5 MU three times per week for 15 months (n = 63)." | ( Bastion, Y; Brice, P; Brousse, N; Haïoun, C; Lepage, E; Moreau, P; Solal-Céligny, P; Straetmans, N; Tabah, I; Tilly, H, 1997) |
| "A 34-year-old patient with follicular lymphoma who was treated with CHOP followed by COPP for 3 years, became resistant to treatment in December 1993." | ( Hirayama, Y; Koyama, R; Kuga, T; Matsunaga, T; Nagai, T; Niitsu, Y; Ohta, H; Sakamaki, S, 1997) |
| "Patients with follicular lymphoma (FL) who do not respond to first-line chemotherapy or those who relapse after obtaining a remission have a poor outcome with standard treatment." | ( Brunet, S; Domingo-Albós, A; López, R; Martino, R; Sierra, J; Sureda, A, 1999) |
| "Management of follicular lymphoma after chemotherapy failure has been controversial and has ranged from watchful waiting to high-dose chemotherapy." | ( Blanco, AI; Cabanillas, F; Cox, JD; Ha, CS; Tucker, SL, 1999) |
| "Thirty-three patients with Stage I-III follicular lymphoma were treated with CLI between January 1993 and February 1998." | ( Blanco, AI; Cabanillas, F; Cox, JD; Ha, CS; McLaughlin, P; Tucker, SL; Wilder, RB, 2001) |
| "The best treatment of follicular lymphoma remains to be determined because the long natural history of follicular lymphoma requires mature data for accurate analysis." | ( Avilés, A; Cleto, S; Díaz, N; Díaz-Maqueo, JC; García, EL; Neri, N; Talavera, A, 2001) |
| "Advanced follicular lymphomas, grades I and II, are indolent tumors but are not considered curable with standard therapy." | ( Bard, V; Foon, KA; LaRocca, RV; Rohatgi, N; Sethuraman, G, 2002) |
| "Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy." | ( Braziel, RM; Fisher, RI; Gaynor, ER; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Rivkin, SE; Unger, JM, 2003) |
| "Most patients with follicular lymphoma respond to therapy, and the average survival time in large series is approximately 10 years." | ( Armitage, JO; Hoelzer, D; Rummel, MJ; Tobinai, K, 2004) |
| "Advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL) cannot be cured using conventional chemotherapy." | ( Dreyling, M; Hiddemann, W; Lenz, G, 2004) |
| "FND is efficient in treatment of follicular lymphoma." | ( Hofmanová, Z; Klabusay, M; Korístek, Z; Matuska, M; Mayer, J; Muzikárová, M; Navrátil, M; Oborilová, A; Vásová, I; Vinklárková, J, 2004) |
| "Newly diagnosed advanced follicular lymphoma patients (172 patients) were randomly assigned either to an immunochemotherapy regimen (cyclophosphamide, doxorubicin, teniposide, prednisone, and interferon) or to a high-dose therapy followed by purged autologous stem-cell transplantation." | ( Bertrand, P; Colombat, P; Cornillet-LeFebvre, P; Deconinck, E; Delepine, R; Delwail, V; Desablens, B; Escoffre-Barbe, M; Foussard, C; Gressin, R; Jaubert, J; Jenabian, A; Le Pourhiet-Le Mevel, A; Legouffe, E; Maisonneuve, H; Michenet, P; Milpied, N; Ramee, JF; Thyss, A; Travade, P; Vilque, JP, 2005) |
| "A total of 164 patients with follicular lymphoma (grade 1/2), mantle cell lymphoma or lymphoplasmacytic lymphoma (immunocytoma) was randomised to treatment with vincristine 2 mg (day 1) and prednisone 100 mg/m2 (days 1-5) + bendamustine 60 mg/m2 (days 1-5) or + cyclophosphamide 400 mg/m2 (days 1-5) for a total of eight 21-day cycles." | ( Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C, 2006) |
| "A 48-year-old male patient with follicular lymphoma, grade II, stage IV, was treated with CHOP, ESHAP and MACOP-B, resulting in partial remission." | ( Chinzei, T; Kawano, S; Kondo, S; Kumagai, S; Okamura, A; Okumachi, Y; Saigo, K; Takenokuchi, M, 2006) |
| "Patients with follicular lymphoma (FL) in advanced stages are currently deemed incurable with standard treatments." | ( Arenillas, L; Balaguer, O; Bosch, F; Campo, E; Colomo, L; Ferrer, A; Giné, E; López-Guillermo, A; Montoto, S; Montserrat, E; Muntañola, A; Plancarte, F; Villamor, N, 2006) |
| "Using this method to follow 14 follicular lymphoma patients treated with autologous stem cell transplantation, molecular markers were successfully defined for 12 patients." | ( Berinstein, NL; Boudreau, A; Buckstein, R; Hewitt, K; Imrie, K; Pennell, N; Reis, M; Seth, A; Spaner, D; Woods, A, 2006) |
| "For patients with follicular lymphoma, the respective OR and CR rates were 100% and 86% as firstline therapy, and 87% and 67% as salvage therapy." | ( Carney, D; Januszewicz, EH; Lin, KI; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M, 2006) |
| "In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades." | ( Dreyling, M; Hiddemann, W; Hoster, E; Lengfelder, E; Nickenig, C; Pfreundschuh, M; Reiser, M; Trumper, L; Unterhalt, M; Wandt, H, 2006) |
| "Advanced follicular lymphoma (FL) is incurable with conventional chemotherapy and radiotherapy, and optimal front-line management is controversial." | ( Braziel, RM; Fisher, RI; Leblanc, M; Maloney, DG; Miller, TP; Press, OW; Unger, JM, 2006) |
| "We report a case of follicular lymphoma in which pulmonary cryptococcosis occurred with cladribine therapy." | ( Kobayashi, M; Mizoroki, F; Nagasaki, E; Nozato, A; Okawa, Y; Shimada, T, 2006) |
| "Treatment strategies for follicular lymphoma have not been established." | ( Akaogi, T; Hayashi, H; Horiike, S; Kimura, S; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murotani, Y; Nomura, K; Sako, M; Sawai, N; Shimazaki, C; Taniwaki, M; Yoshikawa, T, 2007) |
| "We report here a patient with relapsed follicular lymphoma who developed secondary acute myeloid leukaemia 15 months after radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan, the fifth described case to date." | ( Boni, G; Cecconi, N; Focosi, D; Galimberti, S; Orciuolo, E; Petrini, M, 2008) |
| "A 24-year-old woman was diagnosed with follicular lymphoma in January 1998: she had developed bulky intra-abdominal lymphadenopathy, with repeated relapse and remission by several chemotherapy treatments." | ( Hatta, Y; Ishizuka, H; Kura, Y; Miura, K; Nakagawa, Y; Sawada, U; Takei, K; Takeuchi, J; Yamazaki, T, 2010) |
| "Furthermore, accumulation of MCs in follicular lymphoma (FL) correlates with unfavourable prognosis after immunochemotherapy." | ( Bono, P; Jantunen, E; Karjalainen-Lindsberg, ML; Kosma, VM; Leppä, S; Taskinen, M, 2010) |
| "Patients with follicular lymphoma (FL) typically experience an indolent course; however, the disease is rarely curable with conventional chemotherapy." | ( Bredeson, C; Ewell, M; Goodman, SA; Horowitz, MM; Kahl, BS; Laport, GG; Negrin, RS; Tomblyn, MR; Vose, JM, 2011) |
| "Given the rarity of follicular lymphoma (FL) in children, there is limited data on which to base treatment recommendations." | ( Dogan, A; Galardy, PJ; Khan, SP; Kumar, R; Rodriguez, V, 2011) |
| "Nevertheless, follicular lymphoma remains incurable and characterized by recurrent relapses requiring additional treatment." | ( Cheson, BD, 2011) |
| "Using 3D MRI, B-cell follicular lymphoma growth was quantified in a Pten(+/-)Lkb1(+/hypo) mouse line, before, during and after repeated treatments with a PI3K inhibitor GDC-0941 (75 mg/kg)." | ( Duce, SL; García-Martínez, JM; Wullschleger, S, 2012) |
| "We report a patient with follicular lymphoma who had false positive results on 18-fluorodeoxyglucose positron emission tomography (FDG-PET) tests for more than six months due to inflammatory reactions continuing over a long period of time after chemotherapy with rituximab." | ( Hara, M; Kohashi, S; Miyagawa, M; Miyazaki, Y; Nakase, K; Nawa, Y, 2012) |
| "Treatment of follicular lymphoma with rituximab is currently recommended at a dose of 375 mg/m(2)." | ( Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M, 2012) |
| "Advanced follicular lymphomas (FL) are considered incurable with conventional chemotherapy and there is no consensus on the best treatment approach." | ( Braziel, RM; Cheson, BD; Czuczman, MS; Dakhil, SR; Fisher, RI; Friedberg, JW; Gopal, AK; Kaminski, M; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Rimsza, LM; Spier, C; Unger, JM, 2013) |
| "Long-term follow up of patients with follicular lymphoma treated in the FL2000 study confirms the sustained clinical benefit of rituximab without long-term toxicity." | ( Audhuy, B; Bachy, E; Belhadj, K; Brice, P; Brousse, N; Cartron, G; Delwail, V; Fermé, C; Feugier, P; Foussard, C; Houot, R; Le Gouill, S; Lefort, S; Maisonneuve, H; Morschhauser, F; Salles, G; Sebban, C; Sonet, A, 2013) |
| "As with other indolent lymphomas, follicular lymphoma is felt to be highly treatable, but ultimately incurable." | ( Cheson, BD; Ujjani, C, 2013) |
| "We describe a patient with transformed follicular lymphoma(FL), expressing p53 but remaining in complete remission(CR) due to bendamustine-rituximab(BR)therapy." | ( Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Hoki, T; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Miura, S; Nagashima, K; Okagawa, Y; Sakurai, T; Yamada, M, 2013) |
| "Radiation therapy of follicular lymphoma has showed consistent results, which demonstrated by 100% of 5-year tumor-specific survival in the whole group, 100% disease-free survival in patients with stage II, the lack of recurrence in the irradiation fields." | ( Vinogradova, IuN, 2013) |
| "According to treatment methods, the 56 follicular lymphoma patients were divided into 2 groups: CHOP group (26 cases) and bortezomib group (30 cases)." | ( Li, YL, 2015) |
| "A middle-aged woman with follicular lymphoma being treated with chemotherapy presented with acute onset atraumatic forearm swelling and severe pain." | ( Alolabi, B; El Bahtimi, R; Jenkinson, RJ; Koo, K; Lesieur, M; Smilovici, B, 2015) |
| "Twenty percent of patients with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial chemoimmunotherapy." | ( Byrtek, M; Casulo, C; Cerhan, JR; Dawson, KL; Farber, CM; Flowers, CR; Friedberg, JW; Hainsworth, JD; Link, BK; Maurer, MJ; Zelenetz, AD; Zhou, X, 2015) |
| "The optimal initial therapy of follicular lymphoma (FL) remains unclear." | ( Ahmed, M; Cheah, CY; Chihara, D; Davis, RE; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Lee, H; Nastoupil, LJ; Neelapu, SS; Oki, Y; Phansalkar, K; Rodriguez, MA; Romaguera, JE; Samaniego, F; Turturro, F; Wang, ML; Westin, JR, 2016) |
| "A 69-year-old Japanese woman with follicular lymphoma with treatment-related myelodysplastic syndrome was negative for the CD20 antibody at the time of her relapse." | ( Ito, S; Ohigashi, H; Shiratori, S; Teshima, T; Tsutsumi, Y, 2016) |
| "An exploratory analysis of 75 follicular lymphoma patients treated with obinutuzumab or rituximab induction therapy (IT) for 4 weeks in the phase II GAUSS study aimed to determine whether positron emission tomography (PET) results could predict progression-free survival (PFS) and tumor response." | ( Baetz, T; Berge, C; Buckstein, R; Caballero, D; Crump, M; Fine, G; Fingerle-Rowson, G; Gaidano, G; Goy, A; Kostakoglu, L; Martinelli, G; Press, O; Sahin, D; Sehn, L, 2017) |
| "Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity." | ( Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Davids, MS; Jung, SH; Leonard, JP; Levine, E; Lewis, LD; Martin, P; Park, SI; Pitcher, B; Smith, SE; Smith, SM; Ujjani, CS, 2016) |
| "Treatment response of follicular lymphomas (FL) is highly variable." | ( Aulitzky, WE; Dengler, MA; Duppel, J; Horn, H; Ott, G; Rosenwald, A; Staiger, AM; van der Kuip, H; Vöhringer, MC, 2017) |
| "Histological transformation (HT) of follicular lymphoma (FL) to an aggressive lymphoma after chemotherapy remains a key issue." | ( Ansell, SM; Burnette, BL; Colgan, JP; Epperla, N; Habermann, TM; Inwards, DJ; Johnston, PB; Macon, WR; Markovic, SN; Micallef, IN; Nowakowski, GS; Pham, AQ; Porrata, LF; Ristow, KM; Wiseman, GA; Witzig, TE, 2017) |
| "A 63-year-old man with follicular lymphoma was administered standard R-CHOP chemotherapy." | ( Aota, Y; Gotoh, A; Hanyu, N; Honma, T; Kitagawa, N; Komatsu, N; Motoya, K; Nakamura, I; Okuda, Y; Udou, R; Yokoyama, T, 2017) |
| "Most patients with follicular lymphoma (FL) experience multiple relapses necessitating subsequent lines of therapy." | ( Anderson, DM; Ansell, SM; Bartlett, NL; Costello, BA; Fehniger, TA; Gomez, F; Griffith, M; Griffith, OL; Krysiak, K; Kuruvilla, JG; LaPlant, BR; Qi, J; Ramirez, C; Reeder, CB; Siegel, BA; Thye, LS, 2018) |
| "Seventy patients with primary follicular lymphomawere in our hospital were treated with R-CHOP chemotherapy, the ALC/AMC value of peripheral blood was recorded, and the prognosis was assessed by the international prognostic index." | ( Cui, Y; Shi, P, 2018) |
| "The treatment of follicular lymphoma (FL) continues to evolve." | ( Leonard, JP, 2019) |
| "New treatment strategies in follicular lymphoma (FL) are driven by a deeper understanding of microenvironmental cues supporting lymphomagenesis, chemoresistance, and immuno-escape." | ( Morschhauser, F; Ysebaert, L, 2020) |
| "The prognosis and treatment options for follicular lymphoma (FL) remain heterogenous." | ( Gui, L; He, X; Liu, P; Qin, Y; Shi, Y; Yang, J; Yang, S; Zhang, C; Zhou, L; Zhou, S; Zhou, Y, 2021) |
| "Treatment for follicular lymphoma (FL) in the elderly is not well standardized." | ( Baldini, L; Balzarotti, M; Boccomini, C; Bolis, S; Chiarenza, A; Ciccone, G; Corradini, P; Evangelista, A; Ferrero, S; Freilone, R; Ladetto, M; Marina Liberati, A; Nassi, L; Novo, M; Puccini, B; Rattotti, S; Rigacci, L; Rusconi, C; Stelitano, C; Tucci, A; Vitolo, U; Volpetti, S, 2021) |
| "In patients with follicular lymphoma, the prolonged clinical course consisting of multiple relapses is a fundamental challenge that requires clinicians to consider how to best balance treatment efficacy while minimizing toxicity and preserving quality of life." | ( Burke, JM; Leslie, LA; Pagel, JM, 2020) |
| "Endoscopic resection of a follicular lymphoma (FL) presenting as a gastric subepithelial tumor (SET), along with periodic follow up can be a treatment option because gastrointestinal FL cells tend to reside in the primary site, which may explain its indolent nature." | ( Choi, CW; Kim, SJ; Kim, TU, 2021) |
| "Front-line treatment for follicular lymphoma has evolved with the introduction of maintenance therapy, bendamustine (Benda), obinutuzumab (G), and lenalidomide (Len)." | ( Habermann, TM; Maurer, MJ; Nowakowski, GS; Qi, X; Wang, ML; Wang, Y; Witzig, TE; Yang, F; Zhou, S, 2022) |
| "Advanced follicular lymphoma with a high tumor burden has historically been treated with chemoimmunotherapy, but the treatment goal for older patients is relief of symptoms." | ( Miyazaki, K, 2022) |
| "A patient with follicular lymphoma treated with obinutuzumab and bendamustine experienced prolonged coronavirus disease-2019 (COVID-19)." | ( Asakura, S; Saito, T; Ueda, Y; Wada, S; Yano, T, 2022) |
| "Asymptomatic patients with follicular lymphoma (FL) and a low tumour burden can be followed without initial therapy, a strategy called watchful waiting (WW)." | ( Annunziata, S; D'Alò, F; Giordano, A; Hohaus, S; Leccisotti, L; Maccora, D; Maiolo, E; Malafronte, R; Rufini, V, 2023) |
| "Thirty-three patients with follicular lymphoma (FL) (n = 20), marginal zone lymphoma (n = 7), and other iNHL were treated with a median follow-up of 30." | ( Coffey, DG; Cowan, AJ; Fromm, JR; Gooley, TA; Gopal, AK; Graf, SA; Greninger, AL; Libby, EN; Lynch, RC; Rasmussen, H; Shadman, M; Smith, SD; Ujjani, CS; Warren, EH, 2023) |
| "Thirty-three patients with follicular lymphoma (FL) (n = 20), marginal zone lymphoma (n = 7), and other iNHL were treated with a median follow-up of 30." | ( Coffey, DG; Cowan, AJ; Fromm, JR; Gooley, TA; Gopal, AK; Graf, SA; Greninger, AL; Libby, EN; Lynch, RC; Rasmussen, H; Shadman, M; Smith, SD; Ujjani, CS; Warren, EH, 2023) |
| "Thirty-three patients with follicular lymphoma (FL) (n = 20), marginal zone lymphoma (n = 7), and other iNHL were treated with a median follow-up of 30." | ( Coffey, DG; Cowan, AJ; Fromm, JR; Gooley, TA; Gopal, AK; Graf, SA; Greninger, AL; Libby, EN; Lynch, RC; Rasmussen, H; Shadman, M; Smith, SD; Ujjani, CS; Warren, EH, 2023) |